These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35673960)

  • 41. COVID-19 Vaccination in Patients with Myasthenia Gravis: A Single-Center Case Series.
    Ruan Z; Tang Y; Li C; Sun C; Zhu Y; Li Z; Chang T
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696220
    [TBL] [Abstract][Full Text] [Related]  

  • 42. COVID-19 in patients with myasthenia gravis: Epidemiology and disease course.
    Businaro P; Vaghi G; Marchioni E; Diamanti L; Arceri S; Bini P; Colombo E; Cosentino G; Alfonsi E; Costa A; Ravaglia S; Mallucci G; Ballante E; Franciotta D; Gastaldi M
    Muscle Nerve; 2021 Aug; 64(2):206-211. PubMed ID: 34031902
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Response to letter to the editor regarding
    Maher DI; Hogarty D; Ben Artsi E
    Orbit; 2022 Oct; 41(5):662-663. PubMed ID: 35686598
    [No Abstract]   [Full Text] [Related]  

  • 44. Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort.
    Lupica A; Di Stefano V; Iacono S; Pignolo A; Quartana M; Gagliardo A; Fierro B; Brighina F
    Neurol Int; 2022 Apr; 14(2):406-416. PubMed ID: 35645352
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial.
    Wu S; Huang J; Zhang Z; Wu J; Zhang J; Hu H; Zhu T; Zhang J; Luo L; Fan P; Wang B; Chen C; Chen Y; Song X; Wang Y; Si W; Sun T; Wang X; Hou L; Chen W
    Lancet Infect Dis; 2021 Dec; 21(12):1654-1664. PubMed ID: 34324836
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Time course of adverse reactions following BNT162b2 vaccination in healthy and allergic disease individuals aged 5-11 years and comparison with individuals aged 12-15 years: an observational and historical cohort study.
    Yoshida M; Kobashi Y; Shimazu Y; Saito H; Yamamoto C; Kawamura T; Wakui M; Takahashi K; Ito N; Nishikawa Y; Zhao T; Tsubokura M
    Eur J Pediatr; 2023 Jan; 182(1):123-133. PubMed ID: 36224435
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Perception and safety analysis of COVID-19 vaccination in cancer patients: A multicenter, real-world study.
    Lee K; Park IH; Oh SC; Seo JH; Jeon MJ; Yu ES; Kim DS; Choi CW; Lim AR; Hyun MH; Kim JW; Kim JH; Choi YJ; Lee S; Park KH; Kim YH; Choi JY; Kim JS; Lee SR; Sung HJ; Kang EJ
    Cancer Med; 2023 Mar; 12(5):5558-5568. PubMed ID: 36373165
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience.
    Županić S; Perić Šitum M; Majdak M; Karakaš M; Bašić S; Sporiš D
    Acta Neurol Belg; 2021 Aug; 121(4):1039-1044. PubMed ID: 33797054
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse effects following COVID-19 vaccination in Iran.
    Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M
    BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immune Response and Safety of SARS-CoV-2 mRNA-1273 Vaccine in Patients With Myasthenia Gravis.
    Reyes-Leiva D; López-Contreras J; Moga E; Pla-Juncà F; Lynton-Pons E; Rojas-Garcia R; Turon-Sans J; Querol L; Olive M; Álvarez-Velasco R; Caballero-Ávila M; Carbayo Á; Vesperinas-Castro A; Domingo P; Illa I; Gallardo E; Cortés-Vicente E
    Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35728947
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Electronic health record derived-impact of COVID-19 on myasthenia gravis.
    Roy B; Kovvuru S; Nalleballe K; Onteddu SR; Nowak RJ
    J Neurol Sci; 2021 Apr; 423():117362. PubMed ID: 33639420
    [No Abstract]   [Full Text] [Related]  

  • 53. Adverse events following immunisation of COVID-19 vaccine among health care workers in the first phase of vaccination.
    Rahmat H; Leelavathi M; Wan Ismail WF
    Med J Malaysia; 2022 Nov; 77(6):637-642. PubMed ID: 36448378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Thymoma pathology and myasthenia gravis outcomes.
    Menon D; Katzberg H; Barnett C; Pal P; Bezjak A; Keshavjee S; Bril V
    Muscle Nerve; 2021 Jun; 63(6):868-873. PubMed ID: 33675078
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
    Strobel SB; Machiraju D; Kälber KA; Hassel JC
    Cancer Immunol Immunother; 2022 Aug; 71(8):2051-2056. PubMed ID: 34940894
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vaccination against COVID-19 does not lead to exacerbation in patients with myasthenia gravis.
    Breiner A; Bourque PR
    Muscle Nerve; 2023 Jan; 67(1):1-2. PubMed ID: 36321578
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
    Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
    Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute onset ocular myasthenia gravis after COVID-19 vaccination: correspondence.
    Mungmunpuntipantip R; Wiwanitkit V
    Orbit; 2022 Oct; 41(5):661. PubMed ID: 35639541
    [No Abstract]   [Full Text] [Related]  

  • 59. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
    Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.